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Purpose: Dyslipidemia is an important risk factor
for cardiovascular disease (CVD). Statins are known
to effectively reduce not only low-density lipoprotein
cholesterol (LDL-C) level but also death and nonfatal
myocardial infarction due to coronary heart disease.
The risk for CVD from atherogenic dyslipidemia
persists when elevated triglyceride (TG) and reduced
high-density lipoprotein cholesterol (HDL-C) levels
are not controlled with statin therapy. Therefore,
statin/fenofibrate combination therapy is more
effective in reducing CVD risk. Here, we assessed the
efficacy and tolerability of pitavastatin/fenofibrate
combination therapy in patients with mixed
dyslipidemia and a high risk for CVD.
Methods: This multicenter, randomized, double-
blind, parallel-group, therapeutic-confirmatory
clinical trial evaluated the efficacy and tolerability of
fixed-dose combination therapy with pitavastatin/
fenofibrate 2/160 mg in Korean patients with a high
risk for CVD and a controlled LDL-C level
(<100 mg/dL) and a TG level of 150e500 mg/dL
after a run-in period with pitavastatin 2 mg alone. In
the 8-week main study, 347 eligible patients were
randomly assigned to receive pitavastatin 2 mg with
or without fenofibrate 160 mg after a run-in period.
In the extension study, patients with controlled LDL-
C and noneHDL-C (<130 mg/dL) levels were
included after the completion of the main study. All
participants in the extension study received the
pitavastatin/fenofibrate combination therapy for 16
weeks for the assessment of the tolerability of long-
term treatment.
Findings: The difference in the mean percentage
change in noneHDL-C from baseline to week 82022between the combination therapy and monotherapy
groups was −12.45% (95% CI, −17.18 to −7.72),
and the combination therapy was associated with a
greater reduction in non-HDL-C. The changes in
lipid profile, including apolipoproteins, fibrinogen,
and high-sensitivity C-reactive protein from baseline
to weeks 4 and 8 were statistically significant with
combination therapy compared to monotherapy at
all time points. Furthermore, the rates of
achievement of noneHDL-C and apolipoprotein B
targets at week 8 in the combination therapy and
monotherapy groups were 88.30% versus 77.98%
(P ¼ 0.0110) and 78.94% versus 68.45%
(P ¼ 0.0021), respectively. The combination therapy
was well tolerated, with a safety profile similar to
that of statin monotherapy.
Implications: In these Korean patients with mixed
dyslipidemia and a high risk for CVD, combination
therapy with pitavastatin/fenofibrate was associated
with a greater reduction in noneHDL-C compared
with that with pitavastatin monotherapy, and a
significantly improvement in other lipid levels.
Moreover, the combination therapy was well
tolerated, with a safety profile similar to that of statin
monotherapy. Therefore, pitavastatin/fenofibrate
combination therapy could be effective and well
tolerated in patients with mixed dyslipidemia.
ClinicalTrials.gov identifier: NCT03618797. (Clin
Ther. 2020;42:2021e2035) © 2020 The Authors.
Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Dyslipidemia is an elevation in plasma cholesterol,
triglyceride (TG), or both, or a low high-density
lipoprotein cholesterol (HDL-C) level, that
contributes to the development of atherosclerosis.
Notably, dyslipidemia is an important risk factor for
cardiovascular disease (CVD). Low-density
lipoprotein cholesterol (LDL-C) transports cholesterol
from the liver to the cells. Particularly, if more
cholesterol is present than is required by the body, it
is retained in the vessel walls, causing atherosclerosis.
Studies have reported that a reduced LDL-C level
reduces CVD-related morbidity and mortality, and
that lowering the LDL-C level is a strategy for
reducing the risk for CVD.1e3 Statin therapy, which
effectively lowers the LDL-C level, has been
recommended in the 2018 American College of
Cardiology/American Heart Association guideline on
the management of blood cholesterol over various
ranges and for multiple purposes. Furthermore, it has
been reported that statin therapy reduces LDL-C
level, as well as coronary heart disease (CHD)-
induced death and nonfatal myocardial infarction.4e6
Pitavastatin demonstrates potent 3-hydroxymethyl-
glutaryl coenzyme A reductase inhibition. However,
high-dose statin therapy, prescribed in patients with
poorly controlled lipid levels, has been associated
with an increased prevalence of complications, such
as diabetes,7 as well as severe myopathy,
rhabdomyolysis, and elevated liver enzymes.8,9 The
use of statins has been limited due to the risk for
CVD from atherogenic dyslipidemia, when an
elevated TG and a reduced HDL-C level due to statin
therapy cannot be controlled properly. However,
combination therapy with fenofibrate can increase the
success rate of dyslipidemia treatment when statin
monotherapy fails to achieve the desired treatment
goals. Fenofibrate, a fibric acid derivative, is known
to reduce TG, apolipoprotein (Apo)-B, HDL-C, and
Apo A1 levels in patients with mixed
dyslipidemia.10,11 Studies have reported that statin/
fenofibrate combination therapy doubled the
cholesterol-controlling effects without increasing the
risk for adverse events.12,13 Moreover, in the
ACCORD (Effects of Combination Lipid Therapy in
Type 2 Diabetes Mellitus)14 study, the risk for CVD
was reduced in patients with atherogenic
dyslipidemia treated with a combination of a statinOctober 2020and fenofibrate, from 17.3% to 12.4% over 4.7
years, compared with statin monotherapy.
Therefore, this study compared the efficacy and
tolerability of pitavastatin/fenofibrate combination
therapy versus pitavastatin monotherapy in high-risk
patients with CHD and mixed dyslipidemia, with
LDL-C levels controlled on statin monotherapy, but




This multicenter, randomized, double-blind,
parallel-group, therapeutic-confirmatory clinical trial
evaluated the efficacy and tolerability of pitavastatin
with or without fenofibrate in high-risk patients with
mixed dyslipidemia. The study was composed of a
main treatment period and an extension period. The
main treatment period included a run-in period of
pitavastatin monotherapy, followed by an 8-week
treatment period, and the extension study included
16 weeks of combination therapy in participants
enrolled in the main study, for the assessment of the
tolerability of long-term treatment.
This study was conducted at 25 Korean institutions
(The Catholic University of Korea, Seoul St. Mary's
Hospital, Seoul, South Korea, and 24 others), and
the protocol was approved by the institutional review
boards at each participating center. All study
participants provided written informed consent. This
study was conducted according to the principles set
forth in the Declaration of Helsinki and the Good
Clinical Practice guidelines (ClinicalTrials.gov
identifier: NCT03618797).
Patients were required to discontinue lipid-lowering
therapy before entering the run-in period. The run-in
period was conducted in participants prescribed
pitavastatin 2 mg and in whom the dose was
consistent for the 4-week run-in period in those
receiving statins or a 6-week run-in period in those
receiving a fibrate before screening. After the run-in
period with pitavastatin 2 mg, patients whose LDL-C
was <100 mg/dL and whose TG was between 150
and 500 mg/dL were randomly assigned to receive
pitavastatin 2 mg with or without fenofibrate 160 mg
for 8 weeks in the main study. In the extension
study, patients with an LDL-C of <100 mg/dL and a
noneHDL-C of <130 mg/dL (measured at a central2023
Clinical Therapeuticslaboratory) were included after the completion of the
main study. All participants in the extension study
received the pitavastatin/fenofibrate 2/160 mg
combination therapy for 16 weeks, regardless of their
treatment arm assignment in the main study, for the
assessment of the tolerability of long-term treatment.
From the start of screening, therapeutic lifestyle
changes were conducted throughout the study
periods according to the protocol (see Appendix in
the online version at https://doi.org/10.1016/j.
clinthera.2020.08.002).
Study Population
The baseline characteristics, such as sex, age,
weight, body mass index, medical history, and risk
factors for CHD were collected (Table I). This study
enrolled men and women aged between 19 and 80
years with documented mixed dyslipidemia and high
CVD risk according to Adult Treatment Panel III
definitions. Patients were required to meet 1 of the
following criteria: (1) history of CHD, (2) history of
other clinical forms of atherosclerotic disease, (3)
diabetes, or (4) CHD risk of 20% over 10 years as
determined by the Framingham risk calculation. The
present study excluded patients who had acute
coronary syndrome within 3 months or heart failure
(New York Heart Association class III/IV) within 6
months before screening; secondary or iatrogenic
dyslipidemia caused by hypothyroidism or nephrotic
syndrome; >2-fold the upper limit of normal level of
aspartate aminotransferase, alanine aminotransferase,
or creatine phosphokinase; disease of the gallbladder
or pancreatitis; elevated serum creatinine level
(2.5 mg/dL); creatinine phosphokinase level >2-fold
the upper limit of normal; hypersensitivity to
hydroxymethylglutaryl coenzyme A reductase
inhibitors, fibrate, and/or ketoprofen; uncontrolled
hypertension (systolic blood pressure of 180 mm
Hg or diastolic blood pressure of 110 mm Hg);
uncontrolled diabetes mellitus (hemoglobin A1c of
9.0%); a history of myopathy; a history of muscle
toxicity with the use of statins or fibrates; in women
(including those of childbearing potential), current or
planned pregnancy and/or breastfeeding or
inadequate method of contraception;
contraindications for participation; inability to
participate based on legal reasons or the
investigator's decision; and/or concurrent drug
therapy that could have interacted with the study2024drug. Patients who underwent a baseline evaluation
and met the eligibility criteria were enrolled.
Eligible patients were randomly assigned to
receive treatment with a fixed-dose combination of
pitavastatin/fenofibrate 2/160 mg (1 capsule) plus a
pitavastatin-matched placebo (1 tablet) (combination
therapy group), or a pitavastatin/fenofibrate-matched
placebo (1 capsule) plus pitavastatin 2 mg (1 tablet)
(monotherapy group), and were followed up as per
routine clinical practice.
Efficacy and Tolerability Assessments
The primary efficacy end point of this study was the
mean percentage change in noneHDL-C from baseline
to the end of the efficacy period (week 8 of treatment).
The secondary efficacy end points included the mean
percentage change in noneHDL-C from baseline to
week 4, as well as the mean percentage changes in
LDL-C, HDL-C, remnant cholesterol (remnant C),
noneHDL-C/HDL-C, LDL-C/HDL-C, total
cholesterol (TC), TG, very low-density lipoprotein
(VLDL)-C, TC/HDL-C, Apo A1, Apo B, Apo B/Apo
A1, fibrinogen, and hs-CRP from baseline to weeks 4
and 8. According to the National Cholesterol
Education Program Adult Treatment Panel III
guideline,15 the target goaleachievement rate was
defined as the percentage of patients who achieved an
LDL-C of <100 mg/dL and a noneHDL-C of
<130 mg/dL; target goaleachievement rates were
calculated at weeks 4 and 8.
All adverse events from the initiation of the run-in
period to the end of extension study were collected
for tolerability assessment. Adverse events, serious
adverse events, and other adverse events resulting in
the termination of treatment were analyzed and are
described as the prevalence (%) and number of
occurrences in each treatment arm. Tolerability in the
main treatment and extension periods were analyzed
separately.
Adherence to treatment was assessed using pill
counts and was calculated as the percentage of the
number of prescribed pills, corrected for the number
of returned pills, divided by the period (in days),
multiplied by 100%.
Statistical Analysis
Continuous data, such as demographics (age,
weight, height, and body mass index), were collected
at baseline and analyzed using the t test or WilcoxonVolume 42 Number 10
S.-H. Ihm et al.rank-sum test. Categorical data, such as sex and
CHD risk factors, were assessed using the c2 test or
the Fisher exact test. Efficacy variables wereTable I. Baseline characteristics of randomized patients






Age, y 61.68 (10.26)
Weight, kg 69.07 (11.39)





























risk 20% by FRS
Yes 15 (8.62)
No 159 (91.38)
BMI ¼ body mass index; CHD ¼ coronary heart disease; FRS
PCI ¼ percutaneous coronary intervention.
October 2020compared between treatment groups using the t test,
and the paired t test was used for comparing the
variables between treatment groups at each timein this study of pitavastatin calcium 2 mg with or







105 (60.69) 221 (63.69)
68 (39.31) 126 (36.31)
61.91 (9.26) 61.79 (9.76) 0.9816
69.68 (11.82) 69.37 (11.59) 0.7816
26.25 (3.46) 26.16 (3.17) 0.9812
6.71 (4.94) 713 (5.18) 0.1257
0.3763
139 (80.35) 272 (78.39)
34 (19.65) 75 (21.61)
0.3172
138 (79.77) 284 (81.84)
35 (20.23) 63 (18.16)
0.8792
111 (64.16) 224 (64.55)
62 (35.84) 123 (35.45)
0.0703
15 (8.67) 41 (11.82)
158 (91.33) 306 (88.18)
0.3508
42 (24.28) 77 (22.19)
131 (75.72) 270 (77.81)
0.7309
41 (23.70) 85 (24.50)
132 (76.30) 262 (75.50)
0.3893
14 (8.09) 24 (6.92)
159 (91.91) 323 (93.08)
0.8589
14 (8.09) 29 (8.36)
159 (91.91) 318 (91.64)
¼ Framingham risk score; MI ¼ myocardial infarction;
2025
Clinical Therapeuticspoint. Differences in the prevalences of adverse events
and serious adverse events observed in the main
treatment and extension periods were evaluated using
the c2 test or the Fisher exact test. All statistical
analyses were performed using SAS statistical
software version 9.4 (SAS Institute, Cary, North
Carolina).RESULTS
Demographic Characteristics
In this study, 347 of the 867 registered participants
were randomized. The tolerability analysis was
performed in 343 participants (172 in the
combination therapy group, 171 in the monotherapy
group) who received study medication and were
included in the tolerability analysis at least once, and
339 participants (171 in the combination therapy
group, 168 in the monotherapy group) were includedFigure 1. Participant flow chart. FAS ¼ full analysis set;
2026in the full analysis set. Among participants included
in the full analysis set, 296 (145 in the combination
therapy group, 151 in monotherapy group) who had
completed the clinical study were included in the per-
protocol set. For the long-term tolerability analysis
during the extension period, 216 participants (113 in
the combination therapy group, 103 in the
monotherapy group) were included. The main
participants for the analysis of the study were
included in the full analysis set (Figure 1).
Patients' demographic characteristics are described
in Table I. The mean (SD) ages were 61.68 (10.26)
and 61.91 (9.26) years in the combination and
monotherapy groups, respectively; mean weight,
69.07 (11.39) and 69.68 (11.82) kg. The mean body
mass index values were 26.06 (2.85) and 26.25
(3.46) kg/m2 in the combination and monotherapy
groups, respectively. There were no statisticallyPPS ¼ per-protocol set.
Volume 42 Number 10
S.-H. Ihm et al.significant differences observed between the 2 groups.
There were also no statistically significant differences
in sex or risk factors.
Primary Efficacy Evaluation
The primary efficacy end point, the mean (SEM)
percentage change in noneHDL-C from baseline to
week 8, was −7.38% (1.72%) in the combination
therapy group and +5.07% (1.68%) in the
monotherapy group. This change was statistically
significant in the 2 groups (P < 0.001 and P < 0.01
vs baseline, respectively). The difference in mean
percentage changes in noneHDL-C from baseline to
week 8 between the combination and monotherapy
groups was −12.45%, which was statistically
significant (95% CI, −17.18 to −7.72; P < 0.001),
with the combination therapy demonstrating a
greater reduction in noneHDL-C compared to the
monotherapy (Figure 2).
Secondary Efficacy Evaluation
The percentage changes in blood concentrations of
noneHDL-C, LDL-C, HDL-C, remnant C, non-
HDL-C/HDL-C, and LDL-C/HDL-C from baseline to
weeks 4 and 8 of study treatment are shown in
Table II. The mean (SEM) percentage changes inFigure 2. Primary efficacy end point: mean (SEM) percen
with pitavastatin calcium 2 mg with or without
October 2020noneHDL-C level from baseline to week 4
were −8.11% (1.45%) and +2.00% (1.34%) in the
combination and monotherapy groups, respectively
(P < 0.001 between groups). This change was
statistically significant in the combination therapy
group (P < 0.001 vs baseline).
In both the combination and monotherapy groups,
the percentage changes in LDL-C level from baseline
to weeks 4 and 8 were statistically significant (all,
P < 0.01). The differences in the mean percentage
changes between the 2 groups were not statistically
significant at either time point. However, the mean
(SEM) percentage changes in remnant C level from
baseline to week 8 were −38.36% (2.60%)
and +1.22% (5.68%) in the combination and
monotherapy groups, respectively (P < 0.001
between groups).
The mean percentage changes in HDL-C level
from baseline to week 4 were +16.54% (1.61%)
and +3.72% (1.30%) in the combination and the
monotherapy groups, respectively (both,
P < 0.01 vs baseline); at week 8, +20.65% (1.80%)
and +2.25% (1.26%) (P < 0.001 and P ¼ NS vs
baseline). These changes were significantly different
between the 2 groups at both time points (both,
P < 0.001).tage changes from baseline in noneHDL-C at week 8
fenofibrate 160 mg. P < 0.001 between groups.
2027
Table II. Lipid measurements with pitavastatin calcium 2 mg with or without fenofibrate 160 mg
Lipid Combination Therapy (n ¼ 174) Monotherapy (n ¼ 173)
Mean (SEM), mg/dL %Change Mean (SEM), mg/dL %Change
Non-HDL-C
Baseline 107.94 (1.29) 108.57 (1.46)
Week 4 99.02 (1.80) −8.11 (1.45)***yyy 109.33 (1.57) 2.00 (1.34)
Week 8 99.05 (1.90) −7.38 (1.72)***yyy 112.86 (1.92) 5.07 (1.68)**
LDL-C
Baseline 77.96 (1.12) e 78.01 (1.10) e
Week 4 81.51 (1.62) 6.42 (2.28)*** 81.03 (1.42) 5.51 (1.87)**
Week 8 82.25 (1.66) 7.73 (2.22)*** 82.57 (1.74) 6.93 (2.18)**
HDL-C
Baseline 42.06 (0.78) e 41.38 (0.80) e
Week 4 48.07 (0.84) 16.54 (1.61)***yyy 42.49 (0.87) 3.72 (1.30)**
Week 8 49.79 (0.91) 20.65 (1.80)***yyy 42.07 (1.80) 2.25 (1.26)
Remnant Cz
Baseline 29.98 (0.84) e 30.65 (1.02) e
Week 4 17.51 (0.70) −37.51 (2.51)***yyy 28.30 (1.15) −2.12 (4.99)
Week 8 16.80 (0.64) −38.36 (2.60)***yyy 30.29 (1.32) 1.22 (5.68)
NoneHDL-C/HDL-C
Baseline 2.72 (0.06) e 2.84 (0.08) e
Week 4 2.20 (0.06) −18.30 (1.77)***yyy 2.78 (0.07) 1.01 (1.98)
Week 8 2.13 (0.06) −19.33 (2.26)***yyy 2.93 (0.09) 6.17 (2.43)*
LDL-C/HDL-C
Baseline 1.95 (0.04) e 2.01 (0.05) e
Week 4 1.80 (0.05) −6.88 (2.12)**yyy 2.03 (0.05) 3.06 (1.75)
Week 8 1.76 (0.05) −7.51 (2.41)**yyy 2.09 (0.05) 6.06 (2.20)**
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
*P < 0.05, **P < 0.01, and ***P < 0.001 versus baseline.
yyyP < 0.001 versus monotherapy.
zRemnant C ¼ total cholesterol e (HDL-C) e (LDL-C).
Clinical TherapeuticsThe mean percentage changes in noneHDL-C/
HDL-C from baseline to week 4 were −18.30%
(1.77%) and +1.01% (1.98%) in the combination
and monotherapy groups, respectively (P < 0.001
and P ¼ NS vs baseline); at week 8, e19.33%
(2.26%) and +6.17% (2.43%) (P < 0.001 and
P < 0.05 vs baseline). These changes were
significantly different between the 2 groups at both
time points (both, P < 0.001).
The mean percentage changes in LDL-C/HDL-C
from baseline to weeks 4 and 8 were significantly
different between the 2 groups at both time points
(both, P < 0.001).2028Changes in Blood Concentrations of TC, TG,
VLDL-C, and Other CVD Risk Factors
Comparisons of the changes in TC, TG, VLDL-C,
TC/HDL-C, Apo A1, Apo B, Apo B/Apo A1, and
fibrinogen from baseline to weeks 4 and 8 of
treatment in the combination and monotherapy
groups are shown in Table III.
The mean (SEM) percentage changes in TC from
baseline to week 4 were −1.42% (1.08%)
and +1.71% (0.99%) in the combination and
monotherapy groups, respectively; at week 8,
e0.18% (1.21%) and +3.60% (1.15%). The
difference in these changes between the 2 groups wasVolume 42 Number 10
S.-H. Ihm et al.statistically significant at both time points (week 4,
P ¼ 0.0330; week 8, P ¼ 0.0244). The mean
percentage changes in TG, VLDL-C, and TC/HDL-C
from baseline to weeks 4 and 8 were significantly
greater in the combination therapy group compared
to the monotherapy group (all, P < 0.001).
The mean (SEM) percentage changes in Apo A1
from baseline to week 4 were +4.40% (1.12%)
and +0.20% (0.82%) in the combination and
monotherapy groups, respectively (P < 0.001 and
P ¼ NS); at week 8, +6.91% (1.28%) and +1.03%
(0.89%) (P < 0.001 and P ¼ NS). The between-
group differences in these changes were statistically
significant at both time points (week 4, P < 0.01;
week 8, P < 0.001). The mean percentage changes in
Apo B from baseline to week 4 were −3.58%
(1.53%) and +3.79% (1.53%) in the combination
and monotherapy groups, respectively (both,
P < 0.05 vs baseline); at week 8, e2.44% (1.66%)
and +5.86% (1.82%) (P ¼ NS and P < 0.01 vs
baseline). The differences in changes were statistically
significant between the 2 groups (both, P < 0.001).
The mean percentage changes in Apo B/Apo A1 from
baseline to week 4 were −6.48% (1.70%)
and +4.51% (1.85%) in the combination and
monotherapy groups, respectively (P < 0.001 and
P < 0.05 vs baseline); at week 8, e6.50% (2.06%)
and +6.13 (2.06%). The differences in these changes
were statistically significant between the 2 groups
(both, P < 0.001).
The mean (SEM) percentage changes in fibrinogen
level at week 4 were −8.52% (1.49%) and +3.83%
(1.80%) in the combination and monotherapy
groups, respectively (P < 0.001 and P < 0.05 vs
baseline); at week 8, e10.23% (1.49%) and +4.43%
(1.61%) (P < 0.001 and P < 0.01 vs baseline). These
changes were significantly different between the 2
groups (both, P < 0.001). The median percentage
changes in hs-CRP at week 4 were −20.00% and 0 in
the combination and monotherapy groups,
respectively; at week 8, e16.67 and 0. These changes
were significantly different between the 2 groups
(week 4, P ¼ 0.0042; week 8, P ¼ 0.0071).
Achievement Rates of Target Goals
Patients who achieved an LDL-C of <100 mg/dL
and/or a noneHDL-C of <130 mg/dL and an Apo B
of <90 mg/dL at week 8 of treatment were included
in the calculation of the target goaleachievement rateOctober 2020(Figure 3). A total of 80.12% (137/171) patients in
the combination therapy group and 77.98% (131/
168) patients in the monotherapy group achieved an
LDL-C of <100 mg/dL; this difference was not
significant.
With regard to noneHDL-C level, the target-
achievement rate at week 8 was greater in the
combination therapy group than in the monotherapy
group (88.30% [151/171] vs 77.98% [131/168];
P ¼ 0.0110). The rates of achievement of both the
LDL-C and noneHDL-C targets at week 8 were
79.53% (136/171) in the combination therapy group
and 69.64% (117/168) in the monotherapy group.
The achievement rate of both the LDL-C and non-
HDL-C targets was significantly greater in the
combination therapy group than in the monotherapy
group (P ¼ 0.0364).
The rate of achievement of the Apo B target goal
(<90 mg/dL) at week 8 was greater with combination
therapy versus monotherapy (78.94% vs 68.45%;
P ¼ 0.0021).
Tolerability Evaluation
Adverse drug reactions were reported in 3.49% (6/
172) and 1.75% (3/171) of patients in the
combination and monotherapy groups, respectively,
during the 8-week treatment period (Table IV).
The rates of adverse drug reactions reported during
the 16-week, long-term tolerability extension study
were 3.54% (4/113) and 8.74% (9/103) in the
combination and monotherapy groups, respectively
(see the Supplemental Table in the online version at
doi:10.1016/j.clinthera.2020.08.002).
There was no difference in drug adherence between
the 2 groups. Drug-adherence rates were 96.50%
(5.53%) in the combination therapy group and
96.77% (6.07%) in the monotherapy group in the
main study (data not shown).
DISCUSSION
In this study, the use of pitavastatin (statin)/fenofibrate
combination therapy was associated with a decrease in
noneHDL-C (primary efficacy end point) that was
significantly greater than that with pitavastatin
monotherapy in these high-risk patients with mixed
dyslipidemia. The LDL-C level was controlled
similarly in the pitavastatin/fenofibrate combination
and pitavastatin monotherapy groups. However, TG,
HDL-C, TC, and other lipids that are difficult to2029
Table III. Lipid, apolipoprotein, fibrinogen, and hs-CRP measurements with pitavastatin calcium 2 mg with or without fenofibrate 160 mg
Parameter Combination Therapy (n ¼ 174) Monotherapy (n ¼ 173)
Mean (SEM), mg/dL %Change Mean (SEM), mg/dL %Change
TC
Baseline 150.00 (1.40) e 150.04 (1.34) e
Week 4 147.09 (1.70) −1.42 (1.08)y 151.82 (1.63) 1.71 (0.99)
Week 8 148.84 (1.90) −0.18 (1.21)y 154.93 (1.95) 3.60 (1.15)**
TG
Baseline 244.92 (5.72) e 255.71 (6.64) e
Week 4 143.40 (4.65) −40.09 (1.57)***yyy 238.10 (7.97) −2.84 (2.97)
Week 8 141.95 (4.80) −39.66 (2.05)***yyy 252.83 (9.48) 2.09 (3.13)
VLDL-C
Baseline 48.98 (1.14) e 51.15 (1.33) e
Week 4 28.68 (0.93) −40.09 (1.57)***yyy 47.62 (1.59) −2.85 (2.97)
Week 8 28.39 (0.96) −39.66 (2.05)***yyy 50.57 (1.90) 2.07 (3.13)
TC/HDL-C
Baseline 3.72 (0.06) e 3.84 (0.08) e
Week 4 3.20 (0.06) −13.31 (1.26)***yyy 3.78 (0.07) 0.04 (1.37)
Week 8 3.13 (0.06) −14.48 (1.57)***yyy 3.93 (0.09) 3.55 (1.63)*
Apo A1
Baseline 135.87 (1.94) e 134.72 (1.84) e
Week 4 139.83 (1.80) 4.40 (1.12)***yy 134.42 (1.90) 0.20 (0.82)
Week 8 143.49 (1.96) 6.91 (1.28)***yyy 135.30 (1.85) 1.03 (0.89)
Apo B
Baseline 79.62 (1.09) e 79.45 (11.10) e
Week 4 76.34 (1.44) −3.58 (1.53)*yyy 80.99 (1.16) 3.79 (1.53)*
Week 8 76.71 (1.43) −2.44 (1.66)yyy 82.76 (1.29) 5.86 (1.82)**
Apo B/Apo A1
Baseline 0.61 (0.01) e 0.61 (0.01) e
Week 4 0.56 (0.01) −6.48 (1.70)***yyy 0.62 (0.01) 4.51 (1.85)*
Week 8 0.55 (0.01) −6.50 (2.06)**yyy 0.63 (0.01) 6.13 (2.06)**
Fibrinogen
Baseline 281.78 (4.88) e 288.39 (4.66) e
Week 4 252.42 (4.72) −8.52 (1.49)***yyy 294.60 (5.55) 3.83 (1.80)*
































































































































































































































































































































































S.-H. Ihm et al.
October 2020control with pitavastatin monotherapy were well
controlled with combination therapy. Combination
therapy was more efficacious in reducing levels of
inflammatory markers such as fibrinogen and hs-CRP
than was monotherapy and had a significant effect
on remnant C, which is one of the parameters of
atherogenic lipoprotein.
Statins are a standard lipid-lowering medication
used for reducing CVD-related morbidity, including
atherosclerosis, in patients with dyslipidemia.
According to the US AHA/ACC guideline on the
management of blood cholesterol (2018),4 various
statin therapy regimens of varying potency are
recommended based on the patient's age, sex, weight,
demographics, and blood cholesterol levels. However,
recent studies have reported that while potent statin
therapy reduces the risk for CVD, it could increase
the risk for diabetes.7,16 Some patients receiving
statin therapy experience muscle pain.9 Dyslipidemia
is known as the main cause of CVD, and the first-line
goal in reducing CVD-related morbidity is to lower
LDL-C.15 However, several studies have indicated
that elevated levels of not only LDL-C but also other
blood lipids (TC, TG, and VLDL) are risk factors for
CVD, and that controlling these lipid levels will
further reduce CVD-related morbidity.4,17,18 In the
present study, reductions from baseline in TC, TG,
and VLDL-C levels at weeks 4 and 8 were
significantly greater with the pitavastatin/fenofibrate
combination therapy compared to those with
pitavastatin monotherapy. In particular, TG and
VLDL-C levels at weeks 4 and 8 were significantly
reduced compared to the baseline levels. The findings
from the present study suggest that pitavastatin/
fenofibrate combination therapy controls levels of
blood lipids in addition to LDL-C, with a possibility
of lowering the risks for CVD-related morbidity and
the adverse events associated with statin
administration.
Fenofibrate is known to reduce the blood
concentrations of TG and VLDL, increasing the
HDL-C level.19 Previous studies have reported
controlled lipid levels with fibrate + statin
combination therapy.12,20,21 In one study, 248
patients with mixed dyslipidemia were treated for 12
weeks with fenofibrate 160 mg with or without
pravastatin 40 mg. That study reported that the
reduction in noneHDL-C was significantly greater in
the combination therapy group compared to that in2031
Figure 3. Rates of achievement of LDL-C, noneHDL-C, LDL-C/noneHDL-C, and apolipoprotein (Apo) B goals
at week 8 with pitavastatin calcium 2 mg with or without fenofibrate 160 mg.
Clinical Therapeuticsthe monotherapy group (−14.1% vs −6.1%;
P ¼ 0.002).19 The patients treated with pravastatin
40 mg for 8 or more weeks achieved an LDL of
100 mg/dL and a TG of 150e400 mg/dL and were
further treated with pravastatin/fenofibrate 160/
40 mg for 12 weeks. It was shown that TG was
reduced by ~23% and HDL-C was increased by 6%
with the combination therapy. In another study,
patients with mixed dyslipidemia and a high or very
high CVD risk, characterized by a TG level of
150 mg/dL and an LDL-C of 70e130 mg/dL
measured after at least 3 months of monotherapy
with any statin (excluding simvastatin 80 mg,
atorvastatin 40 and 80 mg, and rosuvastatin 20 and
40 mg), were treated with a fixed-dose combination
of fenofibrate/simvastatin 145/20 mg or 145/40 mg,
simvastatin 20 or 40 mg, or fenofibrate 145 mg for
12 weeks.12 TG level was significantly reduced and
HDL-C level was significantly increased with both
fenofibrate/simvastatin fixed-dose combination doses
compared with simvastatin alone (treatment
differences, −32% and +7.5%; both, P < 0.001).
The present study had some novelty and strength.
The present study and previous studies2032predominantly differ in their inclusion criteria. Unlike
previous studies, the present study included Korean
patients at high risk for CVD who took statin
monotherapy and had a target goal of LDL-C but in
whom other lipid levels (eg, TG, HDL-C) were
uncontrolled. Therefore, the present study included
patients with a high risk for CVD and whose residual
lipid profiles were not improved even with statin
therapy. In addition, 2 mg of pitavastatin, a
moderate dose of a moderate-intensity statin, was
used as the primary statin. Pitavastatin is a moderate-
intensity statin, but its efficacy and tolerability have
been proved in Asian populations, and studies have
reported a lower prevalence of diabetes in Asian
populations, including the Korean population, using
pitavastatin when compared to other statins.4,21 The
last is the efficacy. In these patients, pitavastatin/
fenofibrate 2/160 mg combination therapy for 8
weeks was associated with reduced TG (by ~40%)
and increased HDL-C (by ~21%), suggesting
excellent TG and HDL-C results compared to those
in previous studies, despite the short treatment
duration. Considering the results from previous
studies, pitavastatin/fenofibrate combination therapyVolume 42 Number 10
Table IV. Adverse drug reactions with pitavastatin calcium 2 mg with or without fenofibrate 160 mg. Data are
given as number (%) of patients, number of events.






Investigations 4 (2.33), 6 1 (0.58), 2 5 (1.46), 8
ALT elevated 2 (1.16), 2 1 (0.58), 1 3 (0.87), 3
AST elevated 2 (1.16), 2 0 2 (0.58), 2
GGT elevated 1 (0.58), 1 1 (0.58), 1 2 (0.58), 2
LFT abnormal 1 (0.58), 1 0 1 (0.29), 1
GI disorder 2 (1.16), 2 1 (0.58), 1 3 (0.87), 3
Gastritis 0 1 (0.58), 1 1 (0.29), 1
GERD 1 (0.58), 1 0 1 (0.29), 1
Nausea 1 (0.58), 1 0 1 (0.29), 1
CNS disorders 1 (0.58), 1 0 1 (0.29), 1
Headache 1 (0.58), 1 0 1 (0.29), 1
Musculoskeletal and
connective tissue disorders
0 1 (0.58), 1 1 (0.29), 1
Muscle spasms 0 1 (0.58), 1 1 (0.29), 1
Total 6 (3.49), 9 3 (1.75), 4 9 (2.62), 13
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; GERD ¼ gastroesophageal reflux disease; GGT ¼ g-
Glutamyl transferase; GI ¼ gastrointestinal; LFT ¼ liver function test.
S.-H. Ihm et al.was associated with not only a reduced TG level and
an increased HDL-C level, but further control of
elevated blood lipid levels and inflammatory markers
known as CVD risk factors, thereby reducing CVD-
related morbidity in patients with mixed dyslipidemia.
Elevated levels of Apo A1 and B, which are
components of LDL-C and HDL-C that play a role
in metabolism, as well as fibrinogen and hs-CRP, are
known risk factors for CVD.22 In the present study,
the use of the pitavastatin/fenofibrate combination
therapy was associated with a statistically significant
increase in the level of Apo A1 compared to that
with pitavastatin monotherapy. A decreased Apo B
level is considered an important treatment goal in
addition to lowered LDL-C and noneHDL-C. In the
current study, the Apo B level was significantly
decreased. The mean percentage changes in this level
at weeks 4 and 8 were statistically different
compared to the baseline level. Fibrinogen and hs-
CRP are the most well-studied inflammatory markers
of atherothrombosis and CVD risk. In the present
study, the use of the pitavastatin/fenofibrate
combination therapy was associated with statisticallyOctober 2020significant reductions in fibrinogen and hs-CRP
compared with those with monotherapy. It is
considered that pitavastatin/fenofibrate combination
therapy reduces CVD risk factors, in addition to
controlling blood lipid levels, effectively decreasing
CVD-related morbidity in patients with dyslipidemia.
The main tolerability concern with statin/fenofibrate
combination therapy is myopathy.23 However, there
were no reports of myopathy during the main
treatment period in the pitavastatin/fenofibrate group,
with 1 case each reported in the pitavastatin/
fenofibrate combination and pitavastatin
monotherapy groups (0.88% vs 0.97%) during the
extension period, suggesting that the combination
therapy was well tolerated.
The limitations of the present study included a short
treatment period and a lack of study-population
diversity. Furthermore, the present study did not
assess the efficacy or tolerability of the treatment in
elderly patients or in patients with liver or renal
dysfunction, owing to the low recruitment in these
special patient populations. Additionally, the number
of patients with a history of CVD was low and with2033
Clinical Therapeuticssignificant bias, leading to a limitation in the accurate
analysis of the tolerability data. Additional studies
are crucial for subgroup analysis. LDL-C was
increased in both treatment groups. However, the
mean increase in LDL-C was around 5 mg/dL in
both groups. The mean LDL-C level was increased
until 8 weeks and then fell to near-baseline by 24
weeks (extension period) in both groups. This
phenomenon may have been the result of the
relatively short administration period (8 weeks).
Another possibility is that the participants did not
strictly maintain their therapeutic lifestyle changes.
This was another limitation of this study. However,
the target LDL-C level in the high-risk group was
<100 mg/dL, and the LDL-C levels in most of the
participants were within the recommended range at
baseline and at 4, 8, and 24 weeks of drug
administration.
Despite these limitations, in patients with LDL-C
controlled on pitavastatin, the addition of fenofibrate
therapy further regulated the level of LDL-C and
other blood lipids known to be CVD risk factors. In
regard to the tolerability of the combination therapy,
the current study did not report any adverse reactions
additional to those already associated with
fenofibrate therapy, suggesting that the pitavastatin/
fenofibrate combination is well tolerated.CONCLUSIONS
In these Korean patients with mixed dyslipidemia and
at high risk for CVD, the combination of
pitavastatin/fenofibrate was associated with a greater
reduction in noneHDL-C than was pitavastatin
monotherapy, with significant improvements in other
lipid levels. Moreover, the combination therapy was
well tolerated, with a safety profile similar to that of
monotherapy. Therefore, pitavastatin/fenofibrate
combination therapy could be effective and well
tolerated in patients with mixed dyslipidemia.DISCLOSURES
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Clinical TherapeuticsAPPENDIXSupplemental Table 1. Adverse drug reactions during the extension period
Extension period
Combination therapy group Monotherapy group Total
Investigations 1 (0.88) 1 5 (4.85) 5 6 (2.78) 6
Blood creatinine phosphokinase increased 1 (0.88) 1 3 (2.91) 3 4 (1.85) 4
Blood creatinine increased 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Gamma-glutamyltransferase increased 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Gastrointestinal disorders 0 (0.00) 0 2 (1.94) 2 2 (0.93) 2
Abdominal pain 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Gastritis 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Infections and infestations 1 (0.88) 1 0 (0.00) 0 1 (0.46) 1
Cystitis 1 (0.88) 1 0 (0.00) 0 1 (0.46) 1
Musculoskeletal and
connective tissue disorders
1 (0.88) 1 1 (0.97) 1 1 (0.46) 1
Muscle spasms 1 (0.88) 1 1 (0.97) 1 1 (0.46) 1
Nervous system disorders 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Dizziness 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Psychiatric disorders 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Insomnia 0 (0.00) 0 1 (0.97) 1 1 (0.46) 1
Vascular disorders 1 (0.88) 1 0 (0.00) 0 1 (0.46) 1
Hypertension 1 (0.88) 1 0 (0.00) 0 1 (0.46) 1
Total 4 (3.54) 4 9 (8.74) 9 13 (6.02) 13
Data are presented as number of patients (%) number of events.APPENDIX e PROTOCOL FOR THERAPEUTIC
LIFESTYLE CHANGES: GUIDELINE ON DIET
AND EXERCISE FOR THERAPEUTIC LIFESTYLE
CHANGES (TLC)
Patients with dyslipidemia should make the lifestyle
changes recommended by the Guideline on Diet and
Exercise for Therapeutic Lifestyle Changes (TLC).
The basic recommendations are as follows:
 Lose weight if obese;
 Reduce total fat consumption;
 Replace saturated fat (e.g., animal oil) with
unsaturated fat (e.g., vegetable oil, fish, etc.);
 Eat grains rich in fiber and eat a sufficient amount of
vegetables;
 Avoid foods rich in cholesterol as much as possible;
 Avoid overeating;2035.e1 Do not eat too much sugar;
 Drink less d Limit alcohol consumption to 1e2
times per week, and drink only 1 or 2 glasses on
each occasion (regardless of the type of alcohol).1. Diet guidelines
1) Body weight and energy
When you intake more energy than required, the
unused energy promotes the synthesis of triglycerides
and cholesterol in the liver, thereby increasing the
blood concentrations of cholesterol and triglycerides.
Therefore, a patient with hypercholesterolemia with a
higher-than-normal body weight must first try to
return to a normal weight by managing his diet.Volume 42 Number 10
S.-H. Ihm et al.2) Cholesterol
Serum cholesterol levels are affected by the amount
of cholesterol ingested from food and the amount of
endogenous cholesterol synthesized in the liver and
other organs. Thus, the guideline recommends a daily
cholesterol intake of 200 mg or less to lower the
serum level of LDL cholesterol.
3) FatOcto(1) Saturated fatDairy products, meat, palm oil,
and coconut oil, which are high in saturated
fat, should be avoided. Saturated fat intake
should be no more than 7% of the total
energy intake.
(2) Trans fatExcessive trans-fat intake increases
the serum level of LDL cholesterol and
lowers that of HDL cholesterol. Trans fat
intake should be no more than 1% of the
total energy intake.
(3) Polyunsaturated fatty acidsPolyunsaturated
fatty acids include omega-3 and omega-6
fatty acids. Omega-6 fatty acids are known
to lower the serum levels of LDL
cholesterol, HDL cholesterol, and
triglycerides. Since increasing omega-6 fattyFood type Recommend
daily intake
Foods rich in cholesterol
whose intake must
be limited























ber 2020acid intake increases the total fat intake,
omega-6 fatty acid intake should not be
more than 10% of the total energy
intake.Omega-3 fatty acids are known to
lower the serum level of triglycerides and
prevents cardiovascular diseases. The
American Heart Association recommends a
daily omega-3 fatty acid intake of 2~4 g/
day to lower the serum triglyceride level
and 1 g/day to prevent cardiovascular
diseases.4) Dietary fiberWhile insoluble fiber (e.g., wheat
husk) does not significantly affect serum
cholesterol, soluble fiber (e.g., pectin, alginic
acid, etc.) lowers serum cholesterol levels. A
daily insoluble fiber intake of 5~10 g/day can
lower the serum level of LDL cholesterol by 5%.
5) CarbohydratesCarbohydrates rich in soluble
fiber, such as grains, marine algae, vegetables,
and fruits, are recommended. Daily
carbohydrate intake should be no more than
60% of the total energy intake.
6) AlcoholSince excessive drinking can promote
triglyceride synthesis in the liver, it is
recommended to drink no more than two
glasses per day.Examples
squid, animal organ meat, poultry skin, etc.
at (pork belly, bacon, rib, ham, sausage, beef
up, tripe, etc.), dairy products (butter,
whipped cream, etc.), greasy confectioneries
oughnut, pie, pastries, cookies, etc.), palm oil
creamer, instant noodles, snacks, etc.), etc.
, snacks containing shortening, muffin,
oneries, fried food, etc.
fatty acid: corn oil, soybean oil, cottonseed
lla oil, etc.
fatty acid: Tuna, mackerel pikes, salmon,
l, sardine, herring, etc.





Dietary fiber Soluble fiber:
10~25 g/day
Fruits, vegetables, grains, marine algae, etc.






Unrefined whole grains, beans, vegetables, and fruits
low in sugar.
*Avoid grain products such as bread, noodles, rice
cake, potatoes, sweet potatoes, muk, and corn.
Replace white rice and flour with mixed grains, brown
rice, and whole wheat rich in fiber.
Others Reduce the amount of sugar, starch syrup, and honey
used in cooking. Avoid sugary snacks (drinks, bread,
candies, and chocolates, etc.).
Clinical Therapeutics2. Exercise guideline
It is advisable to determine the amount of exercise
needed to effectively lower serum lipid levels based
on daily calorie expenditure.
A patient with hypercholesterolemia must burn at
least 2000 calories per week by exercising
(approximately 300 kcal/day assuming the patient
works out every day) to achieve the desired
outcomes.
The goal of exercise therapy for patients with
hypercholesterolemia is to increase energy
expenditure through aerobic exercise. Aerobic
endurance training, which involves rhythmic
movements of large muscle groups, includes fast
walking, cycling, swimming, and light jogging. All
these activities can improve the cardiopulmonary
function and significantly increase energy expenditure
and are thus appropriate for patients with
hypercholesterolemia.
A patient with hypercholesterolemia must also try to
increase physical activity in daily life. Walking
frequently and when going somewhere near, using
the stairs instead of the elevator, watching less TV,
and avoiding sitting for a long time (for instance,2035.e3before the computer) are examples of lifestyle
changes that can increase one's level of physical
activity during the day.
The exercise intensity needed to improve serum lipid
levels is lower than that needed to maximally improve
one's strength. Hence, serum lipid levels can be
sufficiently improved by mild-to-moderate-intensity
exercises.
Patients must exercise at least five times per week at
a moderate intensity (walking approximately 100
steps/minute and getting out of breath), which is
40e70% of the maximum intensity. They may work
out one to two times per day and should focus on
increasing the duration rather than the intensity of
the exercise.
Other considerations: different recommendations
may apply for patients with other risk factors such as
obesity and hypertension.
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